Forbes JM - Search Results

1

Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?

Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, Arnstein M, Thorpe SR, Cooper ME, Forbes JM. Coughlan MT, et al. Among authors: forbes jm. Endocrinology. 2007 Feb;148(2):886-95. doi: 10.1210/en.2006-1300. Epub 2006 Nov 16. Endocrinology. 2007. PMID: 17110423

2

The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation.

Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I, Soulis T. Cooper ME, et al. Diabetologia. 2000 May;43(5):660-4. doi: 10.1007/s001250051355. Diabetologia. 2000. PMID: 10855541

3

Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis.

Cao Z, Kelly DJ, Cox A, Casley D, Forbes JM, Martinello P, Dean R, Gilbert RE, Cooper ME. Cao Z, et al. Among authors: forbes jm. Kidney Int. 2000 Dec;58(6):2437-51. doi: 10.1046/j.1523-1755.2000.00427.x. Kidney Int. 2000. PMID: 11115077 Free article.

4

Renoprotective effects of a novel inhibitor of advanced glycation.

Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME. Forbes JM, et al. Diabetologia. 2001 Jan;44(1):108-14. doi: 10.1007/s001250051587. Diabetologia. 2001. PMID: 11206401

5

Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).

Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME. Oldfield MD, et al. Among authors: forbes jm. J Clin Invest. 2001 Dec;108(12):1853-63. doi: 10.1172/JCI11951. J Clin Invest. 2001. PMID: 11748269 Free PMC article.

6

Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria.

Forbes JM, Bonnet F, Russo LM, Burns WC, Cao Z, Candido R, Kawachi H, Allen TJ, Cooper ME, Jerums G, Osicka TM. Forbes JM, et al. J Hypertens. 2002 May;20(5):985-92. doi: 10.1097/00004872-200205000-00034. J Hypertens. 2002. PMID: 12011660

7

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.

Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LM, Jerums G, Osicka TM. Forbes JM, et al. Diabetes. 2002 Nov;51(11):3274-82. doi: 10.2337/diabetes.51.11.3274. Diabetes. 2002. PMID: 12401719

8

Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine.

Twigg SM, Cao Z, MCLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME. Twigg SM, et al. Among authors: forbes jm. Endocrinology. 2002 Dec;143(12):4907-15. doi: 10.1210/en.2002-220619. Endocrinology. 2002. PMID: 12446618

9

A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.

Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM. Candido R, et al. Among authors: forbes jm. Circ Res. 2003 Apr 18;92(7):785-92. doi: 10.1161/01.RES.0000065620.39919.20. Epub 2003 Mar 6. Circ Res. 2003. PMID: 12623881

10

Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.

Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Tikellis C, et al. Among authors: forbes jm. Hypertension. 2003 Mar;41(3):392-7. doi: 10.1161/01.HYP.0000060689.38912.CB. Epub 2003 Feb 24. Hypertension. 2003. PMID: 12623933

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

294 results

Search Page

Filters